A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Men 18 years & older

• Confirmed diagnosis of prostate cancer with bone metastases

Exclusion Criteria:

• No more than 2 prior chemotherapy regimens

• No radiation, chemotherapy or bisphosphonates in the past 4 weeks